Skip to content

Effect of Suprascapular Nerve Block and Axillary Nerve Block After Arthroscopic Rotator Cuff Repair

Effect of Ultrasound-guided Suprascapular Nerve Block and Axillary Nerve Block in Relieving Postoperative Pain After Arthroscopic Rotator Cuff Repair

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06055478
Enrollment
71
Registered
2023-09-26
Start date
2023-10-16
Completion date
2025-05-30
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator Cuff Tears

Keywords

suprascapular nerve block(SSNB), axillary nerve block(ANB), visual analog pain scale(VAS), patient's satisfaction(SAT), pain related cytokines, arthroscopic rotator cuff repair

Brief summary

The goal of this clinical trial is to verify the effect of suprascapular nerve block and axillary nerve block in relieving postoperative pain after arthroscopic rotator cuff repair. Are there differences in visual analog pain scale and patient's satisfaction? Are there differences in mean plasma pain related cytokines? The participants will undergo preemptive ultrasound guided suprascapular nerve block and axillary nerve block using each 0.75% ropivacaine 10mL or each 0.9% saline 10mL.

Interventions

PROCEDUREPreemptive ultrasound-guided suprascapular nerve block and axillary nerve block

Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine or saline. Low fixed dose patient controlled analgesia (PCA) were done in the two group.

Sponsors

Chuncheon Sacred Heart Hospital
Lead SponsorOTHER
Hallym University Medical Center
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

An independent nurse uses a random number generator and allocates paticipants into the two group. Participant, investigator, and outcome assessor are blinded of the allocation information.

Intervention model description

Study group: Preemptive US guided suprascapular nerve block (SSNB) and axillary nerve block (ANB) using each 0.75% ropivacaine 10mL Control group: Preemptive US guided suprascapular nerve block (SSNB) and axillary nerve block (ANB) using each 0.9% saline 10mL

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* a definite rotator cuff tear that needed repair seen on preoperative magnetic resonancce imaging (MRI) * acceptance of arthroscopic surgery including rotator cuff repair * age same as or more than 20 years * acceptance of preemptive regional block and PCA, and blood testing

Exclusion criteria

* did not undergo arthroscopic rotator cuff repair * stopped PCA before 48 hours postoperatively because of associated side effects * a history of previous ipsilateral shoulder operation or fracture * a concomitant neurologic disorder around the shoulder * a failure of blood sampling including hemolysis, etc.

Design outcomes

Primary

MeasureTime frameDescription
visual analog pain scale (VAS)preoperative, postoperative 1, 3, 6, 12, 18, 24, 36, 48 hour(s)0-10, 0: no pain, 10: very severe pain

Secondary

MeasureTime frameDescription
Patient's satisfaction (SAT)preoperative, postoperative 1, 3, 6, 12, 18, 24, 36, 48 hour(s)0-10, 0: not satisfied, 10: very much satisfied
IL-6preoperative, postoperative 1, 6, 12, 24, 48 hour(s)pg/mL
IL-8preoperative, postoperative 1, 6, 12, 24, 48 hour(s)pg/mL
IL-1βpreoperative, postoperative 1, 6, 12, 24, 48 hour(s)pg/mL
Substance Ppreoperative, postoperative 1, 6, 12, 24, 48 hour(s)pg/mL
Serotoninpreoperative, postoperative 1, 6, 12, 24, 48 hour(s)ng/mL
β -endorphinpreoperative, postoperative 1, 6, 12, 24, 48 hour(s)pg/mL
norepinephrinepreoperative, postoperative 1, 6, 12, 24, 48 hour(s)pg/mL

Countries

South Korea

Contacts

PRINCIPAL_INVESTIGATORJung-Taek Hwang, MD,PhD

Hallym University Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026